X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aurobindo Pharma Fact Sheet, Aurobindo Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Fact Sheet   (AUBD)

Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

AUROBINDO PHARMA Price History

Price Rs 618.5
Mkt Cap Rs m 361,927
Vol '000 66.5
P/E X 15.0
P/CF X 13.3
EPS (TTM) Rs 41.1
% ch % 0.2
No. of shares m 585.17
% ch week % -0.3
% ch 1-mth % 8.3
% ch 12-mth % -2.5
52 week H/L Rs 809.0/504.0
(As on Apr 20, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AUROBINDO PHARMA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
AUROBINDO PHARMA EQUITY SHARE DATA
High Rs2055451,2801,541895 
Low Rs100139509582622 
Sales per share (Unadj.) Rs201.1277.9415.1235.8254.6 
Earnings per share (Unadj.) Rs10.140.254.034.639.3 
Diluted earnings per shareRs5.020.026.934.639.3 
Cash flow per share (Unadj.) Rs18.651.065.441.346.6 
Dividends per share (Unadj.) Rs1.503.004.502.502.50 
Adj. dividends per shareRs0.751.492.252.502.50 
Dividend yield (eoy) %1.00.90.50.20.3 
Book value per share (Unadj.) Rs89.5128.7184.5124.5160.0 
Adj. book value per shareRs44.564.192.0124.5160.2 
Shares outstanding (eoy) m291.21291.46291.98585.17585.88 
Bonus/Rights/Conversions  ---PREFESOP 
Price / Sales ratio x0.81.22.24.53.0 
Avg P/E ratio x15.18.516.630.719.3 
P/CF ratio (eoy) x8.26.713.725.716.3 
Price / Book Value ratio x1.72.74.88.54.7 
Dividend payout %14.97.58.37.26.4 
Avg Mkt Cap Rs m44,35199,577261,147621,041444,390 
No. of employees `0008.89.511.613.314.0 
Total wages/salary Rs m6,6338,02413,02315,42617,678 
Avg. sales/employee Rs Th6,653.88,526.110,469.510,384.310,667.8 
Avg. wages/employee Rs Th753.8844.71,124.91,160.91,264.3 
Avg. net profit/employee Rs Th333.91,234.61,361.11,522.91,645.8 
AUROBINDO PHARMA INCOME DATA
Net Sales Rs m58,55380,998121,205137,986149,157 
Other income Rs m2852169672,0381,159 
Total revenues Rs m58,83981,214122,172140,024150,316 
Gross profit Rs m8,61021,33725,63631,88234,343 
Depreciation Rs m2,4873,1253,3263,9244,276 
Interest Rs m2,6663,1021,5992,568667 
Profit before tax Rs m3,74115,32521,67927,42930,558 
Minority Interest Rs m2538451550 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m8273,6355,9667,2077,597 
Profit after tax Rs m2,93911,72915,75820,23623,012 
Gross profit margin %14.726.321.223.123.0 
Effective tax rate %22.123.727.526.324.9 
Net profit margin %5.014.513.014.715.4 
AUROBINDO PHARMA BALANCE SHEET DATA
Current assets Rs m41,36856,31283,794102,94492,062 
Current liabilities Rs m34,30842,20060,81478,40266,223 
Net working cap to sales %12.117.419.017.817.3 
Current ratio x1.21.31.41.31.4 
Inventory Days Days120107108107106 
Debtors Days Days10011910712268 
Net fixed assets Rs m28,57427,36639,21850,27862,919 
Share capital Rs m291292292585586 
"Free" reserves Rs m25,06235,80253,56572,28893,133 
Net worth Rs m26,05837,50253,85772,87393,719 
Long term debt Rs m11,48312,79413,1117,4281,814 
Total assets Rs m72,77894,898128,124159,202162,494 
Interest coverage x2.45.914.611.746.8 
Debt to equity ratio x0.40.30.20.10 
Sales to assets ratio x0.80.90.90.90.9 
Return on assets %7.715.613.514.314.6 
Return on equity %11.331.329.327.824.6 
Return on capital %17.136.734.837.432.7 
Exports to sales %66.165.851.651.40 
Imports to sales %31.226.719.219.00 
Exports (fob) Rs m38,71053,26962,51470,9270 
Imports (cif) Rs m18,27921,60723,27226,1930 
Fx inflow Rs m39,05653,42062,61371,01575,838 
Fx outflow Rs m19,44623,25125,32928,79930,224 
Net fx Rs m19,61030,16937,28442,21645,613 
AUROBINDO PHARMA CASH FLOW
From Operations Rs m 2,749 6,463 12,368 14,198 32,786 
From Investments Rs m -2,463 -8,187 -13,980 -14,452 -17,870 
From Financial Activity Rs m 1,081 1,176 932 3,654 -19,153 
Net Cashflow Rs m 1,366 -548 -680 3,397 -4,239 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 54.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 8.0%
FIIs 27.7%
ADR/GDR 0.0%
Free float 10.2%
Shareholders 69,601
Pledged promoter(s) holding 8.6%
 

Company Information

REGD OFF Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038
E-MAIL cs@aurobindo.com WEB www.aurobindo.com
TELEPHONE (040) 6672 5333 FAX (040) 2374 1080
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR S. R. Batliboi & Assoc.
CHM: K. Ragunathan COMP SEC: A. Mohan Rami Reddy YEAR OF INC: 1986 BSE CODE: 524804 FV (Rs): 1 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   ALEMBIC PHARMA  WOCKHARDT LTD.  PLETHICO PHARMA  BIOCON LTD  VENUS REMEDIES  

Compare AUROBINDO PHARMA With:   ALEMBIC PHARMA  WOCKHARDT LTD.  PLETHICO PHARMA  BIOCON LTD  VENUS REMEDIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; IT Sector Ends 4.8% Higher(Closing)

After opening their day on a negative note, Indian share markets witnessed choppy trades and ended their session on a flat note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Why 2.8 Crore Indians Applied for 90,000 Jobs in Indian Railways(Vivek Kaul's Diary)

Apr 16, 2018

This is an excellent example of the huge underemployment problem in India, which the Modi government refuses to acknowledge.

If Your Broker Calls You, Bang the Phone Down!(Smart Contrarian)

Apr 10, 2018

I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.

How to Pick Great Stocks with Rajeev Thakkar(The 5 Minute Wrapup)

Apr 9, 2018

Rajeev Thakkar tells us how teachings from Vipassana can help you became a better investor.

How Small Caps Can Change the Way You Eat, Sleep, and Drive(Sector Info)

Apr 11, 2018

How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.

This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)

Apr 16, 2018

PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS